Eulexia Pharmaceuticals Files 6-K, Incorporates Press Release
Ticker: EPRX · Form: 6-K · Filed: Aug 2, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, regulatory-filing, press-release
TL;DR
Eulexia Pharma (EUPX) filed a 6-K on Aug 2, incorporating a press release. Check F-10 and S-8 filings for details.
AI Summary
Eulexia Pharmaceuticals Inc. filed a Form 6-K on August 2, 2024, incorporating a press release dated August 2, 2024, as Exhibit 99.1. This filing is incorporated by reference into their existing Registration Statements on Form F-10 (File No. 333-276586) and Form S-8 (File No. 333-278534). The company is based in Victoria, British Columbia, Canada.
Why It Matters
This filing indicates ongoing reporting and potential updates related to Eulexia Pharmaceuticals' securities, which could affect investors tracking the company's regulatory compliance and disclosures.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that incorporates a press release and references existing registration statements, not indicating new material events or financial distress.
Key Numbers
- 001-41923 — SEC File Number (Eulexia Pharmaceuticals Inc.'s SEC file number)
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- August 2, 2024 (date) — Filing and Press Release Date
- 333-276586 (registration_statement_file_number) — Form F-10 Registration Statement
- 333-278534 (registration_statement_file_number) — Form S-8 Registration Statement
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (address) — Registrant's Principal Executive Offices
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information that Eulexia Pharmaceuticals Inc. has made or will make public, distribute, or file with the SEC, specifically incorporating a press release dated August 2, 2024, as Exhibit 99.1.
Which existing registration statements does this filing incorporate by reference?
This filing is incorporated by reference into Eulexia Pharmaceuticals Inc.'s Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is August 2, 2024.
Where is Eulexia Pharmaceuticals Inc. located?
Eulexia Pharmaceuticals Inc. is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada, V8R 5G4.
What type of company is Eulexia Pharmaceuticals Inc. based on its SIC code?
Based on its Standard Industrial Classification (SIC) code of 2834, Eulexia Pharmaceuticals Inc. is in the business of Pharmaceutical Preparations.
Filing Stats: 204 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2024-08-02 07:05:08
Filing Documents
- form6k.htm (6-K) — 12KB
- ex991.htm (EX-99.1) — 18KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000956.txt ( ) — 63KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: August 2, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer